In this installment of Oncology Drug Updates, updates to FDA approvals for pembrolizumab in the treatment of lung cancer and RCC are highlighted.
Our team reviews 2018 conference highlights in oncology care, including studies from ASH, SABCS, and SIO.
Our team reviews the most important advances in oncology in 2018, including those in breast cancer, hematologic cancers, lung cancer, immunotherapy, and more.
The results of a follow-up analysis to the phase III MAVORIC study were presented at the ASH 2018 Annual Meeting & Exposition.
Research presented this week at ESMO studied the efficacy of biosimilars to trastuzumab compared with the reference product in breast cancer.